Pills & Co Essay

Biotech companies’ values are primarily driven by intellectual property, they do not need to rely much on their suppliers. These companies also have relatively easy access to sources of raw materials (such as chemicals), scientific tools, computers and testing equipment.

Also, the company will want to educate the market and buyers. Angiomax should be seen as the newest and best product on the market! What do you think of the Medicines Company’s business model of “rescuing’ abandoned drugs? Just as anything, the company does face the risk of failure. The fact that they are ‘abandoned’ drugs should be a red flag as well. There is a reason and probably multiple reasons why other companies abandoned these drugs. The list could include cost, profit, safety, effectiveness, and much more. You have to wonder why this company thinks they can make a difference in these abandoned drugs. Lets say Angiomax does become a success. Does this mean the other drugs that they promote will be successful as well? Definitely not. Since the Medicines Company doesn’t have much history, they are more at risk with no accountability. Not to mention, they don’t have other drugs on the market that are or attaining FDA approval. I don’t think that the Medicines Company is ready to pursue this business model. Their focus should remain on Angiomax. If Angiomax is a success, how much will this business model change? If Angiomax is a success, I would expect the business model to change slightly. Their plan with rescuing abandoned drugs could be pursues little by little. After the success of Angiomax they will have more exposure. The company could take baby steps towards the company’s ‘next big hit’ due to

This week examines significant developments from biotech companies AstraZeneca (AZN), Relypsa (RLYP), and Mast Therapeutics (MSTX).

In this fast paced world that we live in now it is all but impossible to expect any one to wait for anything these days. We through the innovative technological ideas and inventions you can make anything with in minutes what use to take hours. Everyone wants to be a Chief Executive Officer, (CEO) of a major corporation making millions and billions of dollars over night. No one wants to think through how can they take a company that is barley able to keep it’s door open and it’s employees paid to the next level. No one wants to sit down and make up an strategic plan to move a company to the level of excellence to make the millions and billions. Now a days no one has the gumption to go to the board of directors and say that I want to put the whole company at risk for a few years but when we come out we will be at the next level, and oh yeah if we fail the company most likely will not exist no more.

Genzyme's focus on small, but immensely profitable markets for rare diseases and its novel strategy to stay independent has given it formidable returns. However, its acquisition by

Other players in the biotechnology industry such as Celmatix (a fertility genetic testing company) wants to partner with 23andme so that Celmatix can access the millions of user’s DNA that 23andme has collected, while they have done extensive research and testing to find solutions and treatments for infertility. It seems that even big players in this industry are looking to access 23andme’s data collection through partnerships and business deals, but cannot actually substitute 23andme because they do not have access to the millions of genetic information that 23andme has

Smith Pharmaceuticals is one of these corporations. Over several years, they spent hundreds of millions of dollars on research perfecting the method to synthesize and analyze cDNA – complementary DNA – in the genes LIF and LCK. Mutations in these two genes, as Smith discovered, correlated with and were highly indicative of an increased risk of leukemia. Smith filed a patent on these genes and the process of the diagnostic test, and has since benefited over one million potential leukemia patients with a diagnostic that allows them to take preemptive strikes against the disease – the average cost of leukemia in the Netherlands is $104,386 (de Uyl et al.), and one treatment in the United States costs $178,000 (Chen), while Smith’s test is under $4000, and usually insurance eligible under new Federal law, qualifying as preventative care. As the Economist puts it succinctly, “the point of a patent is to encourage innovation by giving inventors a limited period of exclusive control over the fruits of their labour,” (April 2013). Smith invested these large sums into identifying this gene under the assumption that it would make profit off of these tests due to its rights over the information it gathers – and, important to note, it would not have done so without this financial motivation. Otherwise, it is highly plausible that LIF and LCK’s benefits would lie undiscovered even today, and the one million patients tested at under $4000 would all be undergoing $178000

Older companies are racing to retool and newer companies are seeking parts in the information revolution with DNA at it’s core. IMB, Compaq, DuPoint, and other big pharmaceutical companies are among those interested in the potential for targeting and applying genome data.

The pharmaceutical company undergoes new drug advances, conflicting regulatory laws, and tough economic situations. With all these pressures evolving, Merck & Company felt the need to pursue open innovation strategy because the biotech company is too complicated to navigate on its own. There is so much useful information within and outside of company that would be great advantage to the company. Creating new partnerships, discovering new technological trends and classifying new business opportunities are the leading strategic reasons to take part in open innovation. An open innovation strategy allows companies to contribute ideas from external sources quicker than ideas created contained by its

The company has traditionally made strategic acquisitions of businesses in the pharmaceutical and health- care industry in order to obtain desired patents for research, gain more market powers or expand to a new market. Therefore, there is no doubt if Johnson and Johnson will continue to acquire more firms in the future. As a reference, in only one year of 2013, the company completed the acquisitions of Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical development business focused on drugs to treat hormonally-driven cancers, Flexible Stenting Solutions, Inc., a leading developer of innovative flexible peripheral arterial, venous and biliary stents and Shanghai Elsker Mother & Baby Co., Ltd, a baby care company in China. These acquisitions, along with the Alios BioPharma 's acquisition which will be expected to be complete during the last quarter of 2014, involve challenges and risks. In the event that the company does not successfully integrate these acquisitions into their existing operations so as to realize the expected return on their investment, their results of operations, cash flow or financial condition could be adversely affected.

The comparison of the company profiles led to the insight that in the last few years, Sun Pharma has been on an acquisition sprint expanding its global presence and filling the voids in the global portfolio. On the other hand,

Accomplished aggregate offers of US $ 1.65 billion in 2011, with US generics business representing around 43 for every penny of the aggregate deals including Taro Pharmaceuticals, where Sun Pharma holds a controlling stake of 66 for every penny and 77 for every penny of voting rates. The development in the monetary 2011 was an incredible 104 for each penny over the earlier year. The organization has recorded a stunning 377 ANDAs of which 225 have been approved. Sun’s R&D venture amid it was a great 9.4 for every

Daiichi Sankyo faced criticism after Ranbaxy plans came under the US Food and Drug Administration’s scanner shortly after the acquisition. Even after so many years, Ranbaxy’s inability to overcome its FDA-related problems has put pressure on its promoters and stakeholder. When Sun Pharma acquiring Ranbaxy, Daiichi Sankyo is relieved of the burden of managing Ranbaxy’s problems. It will hold a 9% stake in Sun Pharma, as a result of its current stake in Ranbaxy, though one can expect it to sell that stake eventually. However, Sun Pharma’s management indicated they plan to work together with Daiichi to grow the

Sun Pharma that has been investigated is the fifth largest specialty generic pharmaceutical company in the world with global revenues of over $4.5 billion USD. The company possesses a total of 48 manufacturing facilities across 5 continents . Specifically in the United States, where a large part of their revenues come from, they are the market leader for generics in dermatology.

The biosimilar global industry is currently worth 19.4 billion USD and has seen an 89.1% increase from 2009-2014. One of the major reasons for the consumption of biosimilars is their price. They cost 20-30% less than biologics and are estimated to save 250 billion dollars by 2024. The global biosimilar market saw 311 million dollars in 2010 and is expected to increase to 2-2.5 billion USD by 2015. The second reason is that it saves enormous cost on healthcare. European Union saved 1.4 billion euros in 2009. Lastly, the companies that capture a biosimilar market have a great incentive in generation of enormous revenue. Globally, Sandoz had captured 43% of the biosimilar market and Teva stands second at 25%. (1,2,3)